In Vitro Characterization of Human Cytomegalovirus-Targeting Therapeutic Monoclonal Antibodies LJP538 and LJP539. - Wikidata - wikimedia - TriplyDB

In Vitro Characterization of Human Cytomegalovirus-Targeting Therapeutic Monoclonal Antibodies LJP538 and LJP539.

In Vitro Characterization of Human Cytomegalovirus-Targeting Therapeutic Monoclonal Antibodies LJP538 and LJP539.

http://www.wikidata.org/entity/Q37120061

about

Use of broadly neutralizing antibodies for HIV-1 prevention.Antibody therapies for the prevention and treatment of viral infections.

P2860

Q38764543-95D29CBB-9826-4AEA-B5A4-A17A7819CAB8 Q47143843-E412521E-B116-4B8A-943A-651300FA7338

P2860

In Vitro Characterization of Human Cytomegalovirus-Targeting Therapeutic Monoclonal Antibodies LJP538 and LJP539.

http://www.wikidata.org/entity/Q37120061

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 06 June 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

In Vitro Characterization of H ...... Antibodies LJP538 and LJP539.

@en

In Vitro Characterization of H ...... Antibodies LJP538 and LJP539.

@nl

type

label

In Vitro Characterization of H ...... Antibodies LJP538 and LJP539.

@en

In Vitro Characterization of H ...... Antibodies LJP538 and LJP539.

@nl

prefLabel

In Vitro Characterization of H ...... Antibodies LJP538 and LJP539.

@en

In Vitro Characterization of H ...... Antibodies LJP538 and LJP539.

@nl

P1433

Q37120061-D17D97A6-9CC8-4959-8268-4D7384EB3F68

P1476

Q37120061-44F68FC1-03EC-4C4F-90EC-6F8A8A34728E

P2093

Q37120061-0158C400-6D1E-43BD-BBE4-8D26CD02AB49

Q37120061-3E9B9481-D111-4FBD-BDC7-88ADD79ECFC3

Q37120061-588E6528-E4B4-4DE2-A739-DC975C76A314

Q37120061-64A46D5B-16BB-4DD0-8439-227456D27CBB

Q37120061-6F469495-1A7F-4B35-BB9A-34C38225494E

Q37120061-AF1E408B-9823-487A-992D-D1878BFCD0F3

Q37120061-BF87BB14-91AC-41CF-916F-8B5FC2E10076

Q37120061-CE79FD81-7540-4940-A47C-68E3A86828B8

Q37120061-D46A8102-CB49-4507-9A24-093CC880241D

Q37120061-ED10534D-6C85-46B8-8C4F-E360EABD39A7

P2860

Q37120061-02CDEFD5-010A-47A6-963F-17927FA4036C

Q37120061-038B1658-BDAF-4181-9479-055D51F29014

Q37120061-0DACC301-67A1-40A1-A4DD-6E092A00A6EB

Q37120061-0F3A3366-28B8-4290-88E0-20562D636AD7

Q37120061-13443DDB-FC75-407C-991C-AA29036E9DA7

Q37120061-16D19924-9B89-41EA-A507-61E6D28238AA

Q37120061-27DCADAD-70EA-4F56-94B0-E5189A8F404A

Q37120061-2B268B88-EB4B-4939-A139-8C0120C2941C

Q37120061-32B1D82F-BAF0-40CF-8191-D410675ACDFF

Q37120061-34F526DF-833A-46B5-9C41-0D4E03EBE711

P304

Q37120061-E9497E14-E704-4558-9B9C-19B41C66D2B2

P31

Q37120061-97351C1E-F3A4-46F9-AA30-9AF691370E06

P356

Q37120061-7BE3404D-C6C9-48FA-99A9-D1D71047C2AC

P407

Q37120061-67FBBAA6-F0CC-4A03-BA84-877310C890CE

P433

Q37120061-4FFAAB86-67A2-44E2-9187-E7849F8AAD3C

P478

Q37120061-23CE223B-5AE0-47B5-8CEA-9543394869FA

P50

Q37120061-7044CA53-5F9C-449B-87CA-B691BAB4D358

Q37120061-D1837D9F-4891-463F-B87A-AD4814B04764

P577

Q37120061-9EA93573-2875-46EA-AEAB-5C05D3581FD0

P698

Q37120061-A583DB0F-100F-41E9-99FD-624F2B71DCB9

P921

Q37120061-839D9FD0-3691-4725-9D4B-3B8774B9067D

P932

Q37120061-44E390E0-3E0A-4521-823B-FFEAF335343D

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

In Vitro Characterization of H ...... l Antibodies LJP538 and LJP539

@en

P2093

Adam Feire

http://www.w3.org/2001/XMLSchema#string

Andrea Carfi

http://www.w3.org/2001/XMLSchema#string

Brigitte Wiedmann

http://www.w3.org/2001/XMLSchema#string

Christy M Hebner

http://www.w3.org/2001/XMLSchema#string

Claudio Ciferri

http://www.w3.org/2001/XMLSchema#string

David T Barkan

http://www.w3.org/2001/XMLSchema#string

Hetalkumar D Patel

http://www.w3.org/2001/XMLSchema#string

James J Lin

http://www.w3.org/2001/XMLSchema#string

Nadine Jarousse

http://www.w3.org/2001/XMLSchema#string

Tahmineh Akbarnejad Yazdi

http://www.w3.org/2001/XMLSchema#string

P2860

Vaccine prevention of maternal cytomegalovirus infection

A neutralizing anti-gH/gL monoclonal antibody is protective in the guinea pig model of congenital CMV infection

Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex.

HCMV spread and cell tropism are determined by distinct virus populations.

High-content screening to distinguish between attachment and post-attachment steps of human cytomegalovirus entry into fibroblasts and epithelial cells.

Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism

Structural basis for the recognition of human cytomegalovirus glycoprotein B by a neutralizing human antibody

A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus.

Human Cytomegalovirus gH/gL/gO Promotes the Fusion Step of Entry into All Cell Types, whereas gH/gL/UL128-131 Broadens Virus Tropism through a Distinct Mechanism.

Structure of HCMV glycoprotein B in the postfusion conformation bound to a neutralizing human antibody.

P304

4961-4971

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00382-16

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P50

Peter Skewes-Cox

Pavel A Nikitin

P577

2016-07-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27270290

http://www.w3.org/2001/XMLSchema#string

P921

Cytomegalovirus

P932

4958183

http://www.w3.org/2001/XMLSchema#string